Related Experiment Video
Updated: Jul 11, 2025

14:49
Direct and Indirect Culture Methods for Studying Biodegradable Implant Materials In Vitro
Published on: April 15, 2022
5.1K
Progress of biodegradable polymer application in cardiac occluders
Journal of Biomedical Materials Research. Part B, Applied Biomaterials
|November 17, 2023
Summary
Biodegradable cardiac occluders offer a promising alternative to metal devices for treating congenital heart defects, potentially reducing complications associated with traditional implants.
Area of Science:
- Biomaterials Science
- Cardiovascular Medicine
- Medical Device Engineering
Background:
- Congenital heart defects, particularly cardiac septal defects, are common and often treated with surgery.
- Current occluder devices primarily use Nitinol, leading to complications like thrombosis and cardiac erosion.
- Biodegradable occluders are emerging as a safer alternative to metal-based devices.
Purpose of the Study:
- To review the progress of bioabsorbable cardiac occluders.
- To analyze the pros and cons of various biodegradable polymers for occluder fabrication.
- To discuss future research avenues for biodegradable occluder design.
Main Methods:
- Literature review of research on bioabsorbable cardiac occluders.
- Analysis of studies on biodegradable polymers used in occluder development.
- Synthesis of findings on animal and human trials of bioabsorbable occluders.
Main Results:
- Nitinol-based occluders have limitations, including hemolysis, thrombus formation, and cardiac erosion.
- Several bioabsorbable occluders for septal defects have been developed and tested.
- Different biodegradable polymers present unique advantages and disadvantages for occluder applications.
Conclusions:
- Biodegradable cardiac occluders represent a significant advancement over traditional metal devices.
- Further research into materials and structures is needed to optimize bioabsorbable occluder performance.
- The development of effective biodegradable occluders could improve patient outcomes for congenital heart disease.

